Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors,Xenobiotica

当前位置： X-MOL 学术 › Xenobiotica › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors
Xenobiotica ( IF 1.8 ) Pub Date : 2023-09-04 , DOI: 10.1080/00498254.2023.2250856
Sivacharan Kollipara ₁ , Tausif Ahmed ₂ , Sivadasu Praveen ₁

Affiliation

Encorafenib, a potent BRAF kinase inhibitor undergoes significant metabolism by CYP3A4 (83%) and CYP2C19 (16%) and also a substrate of P-glycoprotein (P-gp). Because of this, encorafenib possesses ...

中文翻译：

基于生理学的药代动力学模型来预测恩科拉非尼的药物相互作用。第一部分：酶抑制剂、诱导剂和转运蛋白抑制剂的模型构建、验证和前瞻性预测

Encorafenib 是一种有效的 BRAF 激酶抑制剂，可通过 CYP3A4 (83%) 和 CYP2C19 (16%) 进行显着代谢，也是 P-糖蛋白 (P-gp) 的底物。正因为如此，恩科拉非尼拥有...

更新日期：2023-09-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>